8-KItem 1.01 · Material AgreementItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

BREAKING: $GILD strikes deal to buy Arcellx — tender offer $115/.share + 1 CVR (up to $5 more if anito‑cel…

Filed with the SEC on · Summarized by InvestorsBot

BREAKING: $GILD strikes deal to buy Arcellx — tender offer $115/.share + 1 CVR (up to $5 more if anito‑cel hits $6B in cumulative sales by 12/31/2029). Insiders ~10.3% locked in. Offer to open soon. 🚨💊 #Mergers #Biotech #GILD #Breaking

ALERT: What this means — Arcellx holders get $115 cash now; plus a non‑tradable CVR that pays $5 only if anito‑cel exceeds $6B global sales by 12/31/2029. Offer stays open min 20 business days & needs antitrust clearances. $GILD 🔍💸 #Investing #CAR‑T #M&A #GILD

Confirmed: Directors/NEA/SR One signed support/tender pacts (~10.3% of shares). Deal requires >50%+1 tendered to close; merger follows via DGCL §251(h). Termination fee if Arcellx takes superior bid: $260M. CVRs not SEC‑registered. $GILD ⚖️📑 #DealNews #Biotech #GILD #Arcellx

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from GILEAD SCIENCES, INC.